Precision medicine marches on and consumers are increasingly in the driver’s seat.
So join us on this week’s edition of MedHeads, MedCityNews.com’s look at the business of innovation in medicine, as we examine this subject and other news from the past week in healthcare.
MedHeads, as it does every Friday, starts at 4 pm Eastern today. Join us via the YouTube embed below or on our Google Hangout On Air page.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
I’ll be joined by MedCity News teammate Stephanie Baum and Meghana Keshavan. But we’ll also add special guest David Kroll, a regular contributor to Forbes who will also moderate the precision medicine panel discussion at MedCity CONVERGE next month. Kroll wrote one of the best analyses of the FDA decision that let 23AndMe back into medical genetic testing.
Companies like 23andMe have also been criticized for overinterpreting the impact of genetic variations, most of which are statistical associations, not necessarily clear cause-and-effect. For example, a preference for the herb, cilantro, was listed in my 23andMe profile as associated with a 10% chance of liking or disliking it. Making a promise based on such a small change is almost meaningless (and my result was exactly the opposite of the one expected with my love of cilantro).
But the truth of the matter is that consumer demand for one’s genetic information is only increasing and we will soon be walking around with our entire DNA sequence on a flash drive or a chip in our health insurance card.
So join David and the rest of the MedCity News team to talk about the week that was in the business of medicine at 4 pm Eastern today.
